A phase Ib study (NCT01390818) tested MEK inhibitor pimasertib and PI3K/mTOR inhibitor voxtalisib in patients with advanced solid tumors, including TNBC and BRAFV600-mutant melanoma patients who progressed on BRAF inhibitors [32]. This evidence concerns the gene MAP2K7 and melanoma.